Prescient Therapeutics Gains FDA Approval for PTX-100 Trial

Prescient Therapeutics Limited (AU:PTX) has released an update.

Prescient Therapeutics Limited has received FDA clearance to proceed with a Phase 2 trial of PTX-100, a promising Ras pathway inhibitor for treating relapsed and refractory cutaneous T-cell lymphomas. This approval marks a significant step for the company, building on encouraging Phase 1b data showing a 42% overall response rate among patients. The trial will be conducted at 15 global sites, potentially paving the way for a breakthrough in cancer therapy.

For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.